Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

AstraZeneca gets FDA breakthrough therapy label for asthma treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2018 | 08:46am CEST
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

(Reuters) - AstraZeneca Plc and Amgen Inc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for their drug to treat a type of severe asthma, potentially speeding up its development and regulatory review.

The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline Nucala.

A breakthrough therapy status is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition and that have shown encouraging early clinical results.

A mid-stage trial in 2017 of 584 patients showed that tezepelumab reduced the annual rate of serious asthma attacks, known as exacerbations, by between 61 percent and 71 percent, depending on dose.

Tezepelumab is currently in late-stage trials.

The drug has shown promise in treating "a broad population of patients with severe asthma, including those ineligible for currently approved biologic therapies," said David Reese, executive vice president of Research and Development at U.S.-based Amgen.

(Reporting by Nivedita Balu in Bengaluru; Editing by Sai Sachin Ravikumar)

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -0.36% 206.46 Delayed Quote.17.94%
ASTRAZENECA 0.28% 5798 Delayed Quote.10.72%
GLAXOSMITHKLINE -0.27% 1530.4 Delayed Quote.16.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
09/25AMGEN : BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed..
PR
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/20AMGEN : New Findings on Drug Development Described by Investigators at Amgen (Pe..
AQ
09/20AMGEN : And Los Angeles County Announce Collaboration To Support Life Science In..
PR
09/20EU approves fifth copy of AbbVie's $18 billion drug Humira
RE
09/20CEO OP-ED : A "Predict and Prevent" Healthcare Model for China
PU
09/19AMGEN : World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure wi..
AQ
09/18AMGEN : Scholars Help Build Communities
PU
09/17AMGEN : World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Wi..
PR
09/17FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine
AQ
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25Coherus Bio's Neulasta biosimilar OK'd in Europe; shares up 6% 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/25Amgen's Blincyto OK'd in Japan for ALL 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
Financials ($)
Sales 2018 23 127 M
EBIT 2018 11 582 M
Net income 2018 8 729 M
Finance 2018 3 583 M
Yield 2018 2,52%
P/E ratio 2018 16,08
P/E ratio 2019 15,54
EV / Sales 2018 5,62x
EV / Sales 2019 5,51x
Capitalization 134 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 204 $
Spread / Average Target -1,2%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN17.94%133 636
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY25.79%188 241